Notice of Results

RNS Number : 3011I

Diaceutics PLC

08 August 2019

 

Diaceutics PLC

("Diaceutics" or the "Company")

Notice of results

Analyst briefing

Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces it will release its interim results for the six months ended 30 June 2019 on Monday 9 September 2019.

Analyst briefing

The Company will host a briefing for analysts which will take place at 11.30am on Monday 9 September 2019 in the City of London. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [e-mail].  

Enquiries:

Diaceutics PLC	www.diaceutics.com
Peter Keeling, Chief Executive Officer	via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)			[phone]
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]
Paul McManus		Mob: [phone]

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies.  The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing.  By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes.  The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects.  The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

 

END

 

 

NORUBSSRKKAWRAR